IP Strategy Summit: Biotech & Pharma

Orange Book Listability

Whether a patent has been properly listed in the Orange Book is emerging as a hotly contested issue in counterclaims, antitrust suits and FTC investigations. In this session, Ron Cahill will explore the evolving legal landscape around Orange Book listability, recent case law, and what it could mean for your next Hatch-Waxman case.

Monetizing IP Assets: Licensing, Collaborations, and Alternative Revenue Streams

In an increasingly competitive and innovation-driven biopharma landscape, companies are looking beyond traditional models to generate value from their intellectual property. In this session, Allen Baum and fellow panelists will explore practical and forward-thinking strategies for monetizing IP assets through licensing agreements, joint ventures, and technology transfer deals.